Oppositely, alternative treatment strategies should be considered, if available, in patients with limited benefit from the upfront therapy, including anti-EGFR-based regimens in RAS/BRAF wild-type tumours;18 BRAF and EGFR inhibitors in BRAF V600E mutant;19 FOLFIRI plus aflibercept or ramucirumab,12,13 trifluridine/tipiracil or regorafenib in RAS mutant.20–24. This evidence concerns the gene EGFR and neoplasm.